Drugs / CARMEGLIPTIN
CARMEGLIPTIN
also known as
CARMEGLIPTIN DIHYDROCHLORIDE · Carmegliptina · Carmegliptine · R-1579 · RO-4876904-001 · RO4876904
Small molecule targets DPP4 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00502710 | Jul 2007 → Apr 2008 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARMEGLIPTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | CARMEGLIPTIN DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | Carmegliptina | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | Carmegliptine | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | R-1579 | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | RO-4876904-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL591118 ↗ |
| Known as | RO4876904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00502710 ↗ |
| Action | Inhibit | “Dipeptidyl peptidase IV inhibitor” CHEMBL591118 ↗1“DPP-IV inhibitor” NCT00502710 ↗ |
| Modality | Small molecule | — CHEMBL591118 ↗ |
| Route | Oral | “12.5mg po daily” NCT00502710 ↗ |
| Target | DPP4 | “Dipeptidyl peptidase IV inhibitor” CHEMBL591118 ↗ |